PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME INCREASE EXTRACELLULAR LEVELS OF SEROTONIN THROUGH INTERACTION WITH SEROTONIN TRANSPORTER PROTEINS EXHIBIT AGONIST ACTIVITY AT SEROTONIN 5HT-2 RECEPTORS
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME INCREASE EXTRACELLULAR LEVELS OF SEROTONIN THROUGH INTERACTION WITH SEROTONIN TRANSPORTER PROTEINS EXHIBIT AGONIST ACTIVITY AT SEROTONIN 5HT-2 RECEPTORS
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME INCREASE EXTRACELLULAR LEVELS OF SEROTONIN THROUGH INTERACTION WITH SEROTONIN TRANSPORTER PROTEINS EXHIBIT AGONIST ACTIVITY AT SEROTONIN 5HT-2 RECEPTORS